Stockscreener 앱 받기
40.90
4.74%
1.85
시간 외 거래:
40.64
-0.26
-0.64%
전일 마감가:
$39.05
열려 있는:
$39.3
하루 거래량:
106.51K
Relative Volume:
0.90
시가총액:
$452.18M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.90%
1개월 성능:
+64.32%
6개월 성능:
+163.02%
1년 성능:
+0.00%
1일 변동 폭
$38.95
$41.00
1주일 범위
$36.00
$41.00
52주 변동 폭
$11.17
$41.00
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
125 STRAFFORD AVE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
40.90 | 431.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics to Report Q2 Financials and Corporate Update on August 14 - MSN
Will Palvella Therapeutics Inc. price bounce be sustainableInvestment Life Cycle Planning Summary - Newser
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Is Palvella Therapeutics Inc. forming a reversal patternFree Reliable Investment Entry Point Signals - Newser
Detecting price anomalies in Palvella Therapeutics Inc. with AIReal Trader Watchlist with Entry Targets - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityAsset Allocation Summary With Future Outlook - Newser
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBreakout Monitoring with Momentum Analysis - Newser
Palvella Therapeutics Inc. stock trend forecastSwing Gain Strategy with Entry Forecast - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockDaily Equity Signal Strength Summary Report - Newser
Key External Factors That Drive Palvella Therapeutics Inc. Stock Price MovementsFree Daily Chart Pattern Stock Forecast - Newser
What institutional flow reveals about Palvella Therapeutics Inc.Equity Forecast with Predictive AI Screener - Newser
Will Palvella Therapeutics Inc. stock recover after recent dropShort-Term Upside Breakout Forecast System - Newser
Risk vs reward if holding onto Palvella Therapeutics Inc.Support and Resistance Zone Summary Chart - Newser
Does Palvella Therapeutics Inc. fit your quant trading modelStock Market Trend and Pattern Analysis - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
Real time scanner hits for Palvella Therapeutics Inc. explainedProfitable Trading Blueprint with Entry Zones - Newser
Palvella Therapeutics Inc. stock volume spike explainedShort Term Profit Strategy with Entry Cues - Newser
Palvella Therapeutics Q2 2025 Earnings Call Scheduled for August 14 | PVLA Stock News - Stock Titan
Analysts Set Expectations for PVLA Q2 Earnings - Defense World
How to read the order book for Palvella Therapeutics Inc.AI Trade Signal Forecast with Chart Logic - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyHigh Yield Signals with Entry Timing - Newser
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
What indicators show strength in Palvella Therapeutics Inc.Weekly Outlook for Short Term Investors - Newser
Raymond James Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
Raymond James initiates Palvella Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Lifesci Capital Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Lifesci Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to “Strong-Buy” - Defense World
Palvella Therapeutics CEO to Share Rare Disease Pipeline Updates at Major Growth Conference - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Upgraded by Lifesci Capital to “Strong-Buy” Rating - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Lifesci Capital - Defense World
Palvella Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Plan for Oversold Reversal Stocks Released - metal.it
Analysts Initiate Coverage on Akero Therapeutics, AeroVironment, Wave Life Sciences, Palvella Therapeutics, and WeRide Inc. - AInvest
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Will Palvella Therapeutics Inc. stock split in the near futureFree Step-by-Step Stock Investment Guide - Newser
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):